Mechanistic comparison of bdb pf 06651600 us11111242 example 5 us9617258 example 5 and spebrutinib based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
6
Shared Targets
46%
Jaccard Similarity
46%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
bdb and spebrutinib share 6 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.462 means 46% of the combined target set is bound by both compounds. The IDF-weighted score of 0.456 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do bdb and spebrutinib have in common?
bdb and spebrutinib share 6 molecular targets with a Jaccard similarity of 46%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can bdb and spebrutinib be combined?
bdb and spebrutinib share 6 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: bdb or spebrutinib?
In the BiohacksAI corpus: bdb has 2 PubMed-indexed studies, spebrutinib has 0 studies.